Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases
A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key N-glycosylation mechanism responsible for suppressing the immune response.
Our first generation of N-glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.
News
Taiho Pharmaceutical and Phost'in Therapeutics announce an Option and License Agreement on the First-in-Class GnT-V inhibitor PhOx430
Montpellier, France – August 2023, 25th
Read more
FRANCE 2030: Phost'in Therapeutics is awarded 1.7m€ in the I-NOV competition to support clinical trial and industrialization of its First-In-Class GnT-V inhibitor
Montpellier, France – July 2023, 4th
Read more
Phost'in Therapeutics and the Gianni Bonadonna Foundation announce First Patients Dosed with the First-In-Class PhOx430 in an adaptive Phase I/II in patients with Advanced Solid Tumors
Montpellier, France – Sept 2022, 14th
Read more
Phost'in Therapeutics joins TechShare 2022, Euronext's paneuropean Pre-IPO training program
Montpellier, France – Mars 2022, 09th
Read more
€10M Series A Boosts Cancer Immunotherapy Hitting Tumor Sugar Coating
LABIOTECH.eu – April 2020, 22nd
Read more
Phost’in Therapeutics raises €10.3m to develop First-in-Class N-glycosylation Inhibitors for Cancer Treatment
Montpellier, France – April 2020, 20th
Read more